HOUSTON, TX. Privately-held medical device firm Procyrion, Inc. has been accepted to present Aortix™, its catheter-deployed circulatory assist device intended for long-term use in the treatment of chronic heart failure at the American College of Cardiology 63rd Annual Scientific Session and Expo (ACC.14) scheduled for March 29–31 in Washington D.C.
The Aortix™ device, conceived by Dr. Reynolds M. Delgado III, Medical Director of Mechanical Support at the Texas Heart Institute, is a percutaneous intra-aortic continuous flow pump delivered by a catheter inserted through the femoral artery and held in place using novel self-expanding anchors. The small size and unique design of the device enable a minimally invasive outpatient procedure that takes about ten minutes to complete. “Our primary focus is to dramatically shift the risk profile of mechanical circulatory support and bring long-term circulatory support to the cath-lab. ACC.14 is a perfect opportunity to present Aortix™ to the world’s leading cardiovascular specialists,” says Procyrion President and CEO Benjamin Hertzog. Focusing on the prevention, diagnosis and treatment of cardiovascular disease, ACC.14 is expected to draw 20,000 attendees from 109 countries to hear from industry experts, participate in Interactive Learning Labs™, view hundreds of new products and hear abstract presentations of the latest discoveries and research that are transforming cardiovascular care.
Procyrion’s team of life science entrepreneurs, cardiologists and circulatory support experts have also been accepted to present Aortix™ at the International Society for Heart and Lung Transplantation’s 34th Annual Meeting & Scientific Session in San Diego April 10–13, 2014.
ABOUT PROCYRION:
Houston-based medical device firm Procyrion, Inc. is developing the first catheter-deployed, intra-aortic pump for ambulatory use. The device is designed to rest and heal the heart by reducing afterload while simultaneously improving blood flow to vital organs. This groundbreaking cardiology tool, conceived by cardiologist Dr. Reynolds M. Delgado, III, medical director of Mechanical Support Devices in Heart Failure at the Texas Heart Institute, is expected to provide a minimally invasive treatment option for millions of chronic heart failure patients. For more information, visit www.procyrion.com or call 713.579.9227.
ABOUT THE AMERICAN COLLEGE OF CARDIOLOGY:
The American College of Cardiology Annual Scientific Session brings together cardiologists and cardiovascular specialists from around the world each year to share the newest discoveries in treatment and prevention. Follow @ACCMediaCenter and #ACC14 for the latest news from the meeting.
The American College of Cardiology, a 43,000-member nonprofit medical society, is dedicated to enhancing the lives of cardiovascular patients through continuous quality improvement, patient-centered care, payment innovation and professionalism. Comprised of physicians, nurses, nurse practitioners, physician assistants, pharmacists and practice managers, the College bestows credentials upon cardiovascular specialists who meet its stringent qualifications. Above all, the ACC’s commitment to its members and their patients has driven the College to be a leader in the formulation of health policy, standards and guidelines, and to be a steadfast supporter of cardiovascular research. For more information, visit www.cardiosource.org
Company Name: Procyrion, Inc.
Contact Person: Anna Drake
Email:Send Email
Phone: 713.510.0500
Address:3900 Essex Lane Suite 575
City: Houston
State: TX
Country: United States
Website: www.procyrion.com
Source: www.abnewswire.com
